- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05179824
Tempus Priority Study: A Pan-tumor Observational Study
April 2, 2024 updated by: Tempus AI
Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Study Overview
Status
Recruiting
Conditions
- Lymphoma
- Leukemia
- Breast Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Lung Cancer
- Prostate Cancer
- Brain Cancer
- Bladder Cancer
- Cancer of Head and Neck
- Peritoneal Cancer
- Cancer of Liver
- Cancer of Stomach
- Cancer of Cervix
- Cancer of Colon
- Cancer of Rectum
- Cancer of Gastrointestinal Tract
- Cancer of Skin
- Cancer of Esophagus
- Cancer of Endometrium
- Cancer of Kidney
- Cancer of Larynx
- Cancer of the Bile Duct
- Cancer of Vulva
- Cancer of Bone and Connective Tissue
- Spinal Cord Cancer
Intervention / Treatment
Detailed Description
The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices.
Participants who agree to join the Study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating Institution for submission to Tempus.
The specific goal of the Study is to create an outcomes-based dataset for future research to improve cancer treatment.
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: PRIORITY Study
- Phone Number: (833) 514-4187
- Email: prioritystudy@tempus.com
Study Locations
-
-
California
-
Napa, California, United States, 94558
- Withdrawn
- Providence Medical Foundation
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Withdrawn
- Community Health
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- Withdrawn
- Pontchartrain Cancer Center
-
-
Missouri
-
Bolivar, Missouri, United States, 65613
- Withdrawn
- Central Care Cancer Center
-
-
New Jersey
-
Belleville, New Jersey, United States, 07109
- Withdrawn
- New Jersey Cancer Center and Blood Disorders, New Jersey Cancer Care
-
-
New York
-
New York, New York, United States, 10016
- Withdrawn
- Perlmutter Cancer Center, NYU Langone Health
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220
- Withdrawn
- TriHealth Cancer Institute- Good Samaritan Hospital
-
Columbus, Ohio, United States, 43214
- Withdrawn
- OhioHealth
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74146
- Withdrawn
- Oklahama Cancer Specialists and Research Institute
-
-
Pennsylvania
-
York, Pennsylvania, United States, 17403
- Withdrawn
- Cancer Care Associates of York
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- UT Southwestern
-
Contact:
- Donna Mitchell
- Phone Number: 214-645-8789
-
Principal Investigator:
- Woldu Solomon
-
Houston, Texas, United States, 77030
- Recruiting
- Baylor College of Medicine
-
Contact:
- Merin Thomas
- Phone Number: 713-798-7291
- Email: merint@bcm.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
This protocol targets a broad spectrum of cancer patients with comprehensive genomic profiling.
Description
Inclusion Criteria:
- Solid or hematologic malignancy.
- Willing and able to provide informed consent where required.
- Has received or will receive genomic profiling.
Exclusion Criteria:
- Individuals without the capacity to consent.
- Prisoners at the time of enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1: Standard of Care (SOC) CGP
This group will facilitate collection of paired clinical and molecular data done as part of the standard of care or routine clinical care across a variety of institutions.
The goal of Group 1 is to capture a broad range of participants to better understand longitudinal outcomes across institutions and standards of care.
|
No Intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Create robust data set of health information
Time Frame: Up to 10 years
|
To create a robust data set of health information about cancer patients who receive comprehensive genomic profiling in order to facilitate future novel precision medicine research
|
Up to 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Document clinical events for patients who have had comprehensive genomic profiling
Time Frame: Up to 10 years
|
To document specific clinical events in relation to diagnosis, treatment, and outcomes for patients who have had comprehensive genomic profiling
|
Up to 10 years
|
Evaluate longitudinal paired tissue and cell free molecular testing
Time Frame: Up to 10 years
|
To evaluate the feasibility of longitudinal paired tissue and cell free molecular testing of participants with specific types of cancer, mutations, or therapies
|
Up to 10 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Support prospective and retrospective research studies
Time Frame: Up to 10 years
|
To support prospective and retrospective research studies on participants with specific cancer types
|
Up to 10 years
|
Describe real world treatment outcomes
Time Frame: Up to 10 years
|
To describe real world treatment outcomes (such as real-world response, real world duration of response, real world progression free survival, real world time to next treatment, real world time to treatment discontinuation, and overall survival)
|
Up to 10 years
|
Review medical information for standard of care decisions and health outcomes
Time Frame: Up to 10 years
|
To review medical information for standard of care decisions in the future and general health outcomes
|
Up to 10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kristiyana Kaneva, MD, MS, MBA, Tempus AI, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. Erratum In: Nat Med. 2017 Aug 4;23 (8):1004.
- Daoud A, Chu QS. Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. Front Oncol. 2017 Sep 29;7:222. doi: 10.3389/fonc.2017.00222. eCollection 2017.
- Ersek JL, Black LJ, Thompson MA, Kim ES. Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices. Am Soc Clin Oncol Educ Book. 2018 May 23;38:188-196. doi: 10.1200/EDBK_200633.
- Griffith SD, Tucker M, Bowser B, Calkins G, Chang CJ, Guardino E, Khozin S, Kraut J, You P, Schrag D, Miksad RA. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. Adv Ther. 2019 Aug;36(8):2122-2136. doi: 10.1007/s12325-019-00970-1. Epub 2019 May 28.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 19, 2020
Primary Completion (Estimated)
October 19, 2026
Study Completion (Estimated)
October 19, 2030
Study Registration Dates
First Submitted
December 16, 2021
First Submitted That Met QC Criteria
December 16, 2021
First Posted (Actual)
January 5, 2022
Study Record Updates
Last Update Posted (Actual)
April 3, 2024
Last Update Submitted That Met QC Criteria
April 2, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Adnexal Diseases
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Liver Diseases
- Musculoskeletal Diseases
- Respiratory Tract Neoplasms
- Otorhinolaryngologic Neoplasms
- Otorhinolaryngologic Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Bone Diseases
- Esophageal Diseases
- Fallopian Tube Diseases
- Colorectal Neoplasms
- Biliary Tract Diseases
- Vulvar Diseases
- Bile Duct Diseases
- Laryngeal Diseases
- Biliary Tract Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms
- Stomach Neoplasms
- Head and Neck Neoplasms
- Fallopian Tube Neoplasms
- Bone Neoplasms
- Rectal Neoplasms
- Endometrial Neoplasms
- Brain Neoplasms
- Gastrointestinal Neoplasms
- Vulvar Neoplasms
- Liver Neoplasms
- Skin Neoplasms
- Esophageal Neoplasms
- Colonic Neoplasms
- Laryngeal Neoplasms
- Bile Duct Neoplasms
Other Study ID Numbers
- TP-CA-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsTerminatedLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Clinical Trials on Observation
-
University of MichiganKuwait Foundation for the Advancement of SciencesCompletedGingival RecessionUnited States
-
Centre Hospitalier Régional d'OrléansCompleted
-
Istanbul University - Cerrahpasa (IUC)CompletedBrachial Plexus Palsy | Obstetric; InjuryTurkey
-
Abant Izzet Baysal UniversityRecruitingMultiple SclerosisTurkey
-
Universidad Autonoma de MadridCompleted
-
Universidad Autonoma de MadridUnknown
-
University of BergenEuropean Society of Intensive Care MedicineCompletedCritical Illness | Old Age; Debility | SurvivalNorway
-
Dokuz Eylul UniversityIzmir Katip Celebi UniversityCompleted
-
Istanbul Medeniyet UniversityIstinye University; Ufuk UniversityRecruiting
-
Clinica Universidad de Navarra, Universidad de...CompletedAnaphylactic ReactionSpain